EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)

Yuzhe Cheng iD, Jingyi Ma, Jun Niu iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0323973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Yuzhe Cheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, General Hospital of Northern Theater Command, Shenyang, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ixekizumab, a monoclonal antibody targeting IL-17A, is approved for psoriasis (PsO) and psoriatic arthritis (PsA). While clinical trials demonstrate its efficacy, real-world safety insights remain critical due to limitations in detecting rare or delayed adverse events (AEs).

Methods

This study analyzed 28,889 ixekizumab-associated AE reports from the first quarter of 2016 to the third quarter of 2024 in the FDA Adverse Event Reporting System (FAERS) using disproportionality methods (ROR, PRR, MGPS, BCPNN) and Weibull distribution modeling. Subgroup and sensitivity analyses were conducted to evaluate demographic variations and confounding factors.

Results

Common AEs included injection site reaction, fungal infections, and upper respiratory infections. Novel signals included myocardial infarction, herpes zoster, and inflammatory bowel disease. Subgroup analyses revealed male-predominant cardiac risks and age-dependent patterns (pediatric injection reactions vs elderly herpes zoster). Median time-to-onset was 56 days (IQR:12–205), with early risk escalation (Weibull β = 0.60).

Conclusions

This FAERS analysis confirms ixekizumab’s established safety profile while identifying critical demographic-specific and delayed-onset signals. Continuous pharmacovigilance is warranted to optimize risk management, particularly for cardiovascular monitoring in high-risk males and antiviral prophylaxis in elderly patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAdverse Drug Reaction Reporting SystemsHumansUnited StatesMaleUnited States Food and Drug AdministrationFemaleMiddle AgedAgedAdultPsoriasisChildAdolescentYoung AdultArthritis, Psoriatic

Substanzen

ixekizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, General Hospital of Northern Theater Command, Shenyang, China.
  • Graduate School, China Medical University, Shenyang, China.

ORCID-Profile: Yuzhe Cheng, Jun Niu

Förderung

  • Department of Science and Technology of Liaoning Province

Zitieren

APA

Cheng, Y., Ma, J., & Niu, J. (2025). Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS). PLOS One. https://doi.org/10.1371/journal.pone.0323973

Vancouver

Cheng Y, Ma J, Niu J. Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS). PLOS One. 2025. doi:10.1371/journal.pone.0323973

BibTeX
@article{Cheng2025,
  author = {Cheng, Yuzhe and Ma, Jingyi and Niu, Jun},
  title = {Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0323973}
}
Kostenlos starten →